Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs By Ogkologos - July 28, 2026 86 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPETE study Source RELATED ARTICLESMORE FROM AUTHOR Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian MOST POPULAR Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer January 11, 2021 COVID-19: “We’ve got so much on our plates” August 4, 2020 Severe mental illness linked to low attendance at cancer screening May 4, 2023 Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to... October 7, 2025 Load more HOT NEWS FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition... 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... Maximizing the Prospects for Progress Against Cancer
